ZIM Laboratories experienced a 5.2% decrease in Q4 sales compared to last year, reporting earnings of INR 102.85 crore. The company's net profit declined by 39.4%, reaching INR 3.28 crore, while EBITDA dropped by 24.1% to INR 12.74 crore for the same quarter.

Zim Laboratories aims to regain its EU Good Manufacturing Practice (GMP) certification by Q2 of the upcoming fiscal year (FY27). The company reported a revenue of approximately Rs. 3,744 million and an EBITDA margin of 12.7% in the last fiscal year (FY26).

Zim Labs' European subsidiary has secured approval from Italy's Medicines Agency for Dabigatran capsules, allowing for a quicker entry into the EU and UK markets. With an estimated EU market value of €393M by 2025, this move could significantly expand Zim Labs' reach in the region.

Zim Laboratories' Q4 EBITDA halved compared to the previous year, decreasing from ₹146M to ₹72M. The profit margin also dipped significantly, falling from 13.4% to 6.8%. This indicates a challenging quarter for the company.

Zim Laboratories successfully passed the European GMP audit conducted by German and Portuguese authorities between May 4-7, 2026, at their Nagpur facility. Further updates will be provided in due course.

Zim Labs has made a significant move by acquiring a 99.96% stake in ZIMTAS, marking an expansion of its investments and boosting its business presence. This purchase amounts to approximately 89.45 lakh rupees.